A retrospective analysis of the CARTITUDE-1 trial suggests that patients who have undergone allogeneic stem cell transplant (allo-SCT) prior to receiving chimeric antigen receptor (CAR) T-cell therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback